Myelodysplastic Syndrome
Conference Coverage
Drug enables transfusion independence in lower-risk MDS
COPENHAGEN—Results from a pair of phase 2 trials suggest luspatercept can produce erythroid responses and enable transfusion independence in...
Conference Coverage
ESA benefits lower-risk MDS patients
COPENHAGEN—The erythropoiesis-stimulating agent (ESA) darbepoetin alfa can provide a clinical benefit in patients with lower-risk myelodysplastic...
News
Study reveals potential treatment avenue for DBA, MDS
The production of two components of hemoglobin may be out of sync in Diamond Blackfan anemia (DBA) and myelodysplastic syndromes (MDS), according...
News
Rigosertib falls short for high-risk myelodysplastic syndromes after failure on azacitidine or decitabine
Key clinical point: Rigosertib failed to extend overall survival beyond that seen with best supportive care in a trial of patients who had...
News
Rigosertib falls short for high-risk myelodysplastic syndromes after failure on azacitidine or decitabine
Key clinical point: Rigosertib failed to extend overall survival beyond that seen with best supportive care in a trial of patients who had...
News
In myelodysplastic syndrome, improved tool for predicting death after HCT
Key clinical point: A portion of patients with myelodysplastic syndrome in high- and very high–risk groups of the revised International Prognostic...
News
Drug exhibits preclinical activity against MDS
Researchers have found the fusion protein APG101 can rescue erythropoiesis in bone marrow samples from patients with lower-risk myelodysplastic...
News
Drug may best BSC in some high-risk MDS patients
Results of a phase 3 trial suggest the small-molecule inhibitor rigosertib may improve overall survival (OS) in some patients with higher-risk...
News
Germline mutations linked to hematologic malignancies
A new study suggests mutations in the gene DDX41 occur in families where hematologic malignancies are common. Previous research showed that both...
News
Generic imatinib launched with savings program
Photo by Rhoda Baer Sun Pharma has announced the US launch of imatinib mesylate tablets, which are a generic version of Novartis’s Gleevec, for...